Compares inhaled insulin with pump insulin for low blood sugar during exercise

Trial details

Who runs it

Jaeb Center for Health Research

Trial code

NCT06880835

Record updated

16 July 2026

Original description

This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.Read full original descriptionShow less

INHALE-AIDEx: A Randomized Crossover Trial Evaluating the Effect of Inhaled Technosphere Insulin (Afrezza®) vs Rapid Acting Analogue Insulin on Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes Using Automated Insulin Delivery

This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.

Inclusion: Ability to provide informed consent for study participation; Age ≥18 years to 65 years; Clinical diagnosis of T1D (per the Investigator); Using Tandem t:slim X2 or Tandem Mobi insulin pump with Control-IQ for at least 90 days prior to screening visit; Using insulin aspart or insulin lispro in Tandem insulin pump; Total daily insulin dose 20 to 80 units; Usual RAA insulin bolus for 50 gram carbohydrate lunch meal is ≤12 units; Physically active, with at least 3 moderate or vigorous exercise sessions ≥30 minutes per typical week self-reported by participant; No medical, psychiatric, or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study; No electrocardiogram (ECG) abnormality that in the judgment of the investigator, which will take into consideration the usual exercise performed by the participant and their overall medical condition, increases the risk of exercise; Investigator believes that the participant can safely follow the protocol; Able to read and understand written and spoken English or Spanish.

Exclusion: Use of inhaled insulin within one week prior to screening visit; Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 90 days prior to screening visit and no plans to smoke during the study; Pregnant or lactating, planning to become pregnant during the study, or is of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal); A pregnancy test is required for any person of childbearing potential; An event of severe hypoglycemia, as judged by the Investigator, within the 90 days prior to screening visit; An episode of diabetic ketoacidosis (DKA) as defined in section 5.2 within the 90 days prior to screening visit; Exposure to any investigational drug in the 90 days prior to the screening visit; Current use of Hydroxyurea medication; History of asthma, chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator; History or current diagnosis of lung cancer; Known stage 4/5 chronic kidney disease or on dialysis; Any disease other than diabetes or current use (or anticipated use during the study) of any medication (e.g., beta blocker) that, in the judgment of the Investigator, may substantially impact glucose metabolism; Use of a non-insulin glucose-lowering medication (or weight-reduction medication with glucose-lowering effect) within 4 weeks prior to screening visit; Forced expiratory volume in 1 second (FEV1) measurement of <70% of predicted Global Lung Function Initiative value; Current or anticipated acute uses of oral, inhaled, or injectable glucocorticoids during the time period of the study (topical or intranasal glucocorticoid use is acceptable); Current or anticipated use of a low carbohydrate diet (<50 grams/day) or low calorie diet (<800 kcal/day) during the time period of the study; Current treatment for diabetic retinopathy; Having a direct supervisor at place of employment who is directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the study.

ClinicalTrials.gov NCT06880835